Skip to main content
Clinical Trials/NCT00159042
NCT00159042
Completed
Not Applicable

Identification of Novel Genetic Modifiers in Beta-thalassemia

Deborah Rund1 site in 1 country50 target enrollmentJuly 2004

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Beta Thalassemia
Sponsor
Deborah Rund
Enrollment
50
Locations
1
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Patients with genetic diseases can have widely differing severities. We are looking for genetic factors which influence the severity of beta thalassemia.

Detailed Description

The understanding of the phenotypic variability of genetically homogeneous disorders represents a major challenge. In beta thalassemia, the beta globin gene is affected by a variety of mutations. The group of patients to be analyzed here is homozygous for a splice site mutation that is common in the Middle East. In contrast to this genetic homogeneity, the spectrum of the clinical phenotype ranges from mild anemia to most severe, transfusion dependent anemia. We will use a genetic linkage approach to identify modifying factors and by analyzing the efficiency of an mRNA surveillance mechanism that is referred to as nonsense-mediated decay and represents a candidate genetic modifier of beta thalassemia and other genetic disorders.

Registry
clinicaltrials.gov
Start Date
July 2004
End Date
July 1, 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Deborah Rund
Responsible Party
Sponsor Investigator
Principal Investigator

Deborah Rund

Senior Hematologist

Hadassah Medical Organization

Eligibility Criteria

Inclusion Criteria

  • Identification of homozygous IVS1 nt 6 beta thalassemia mutation

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials